OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer
17 juin 2009 02h00 HE
|
Oxigene, Inc.
Seasoned Industry Executive With More Than 20 Years of Oncology-Focused Drug
Development Experience
WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a
clinical-stage...
OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting
01 juin 2009 10h45 HE
|
Oxigene, Inc.
Final Data Presentation Shows 25% Confirmed Response Rate in Relapsed Patient
Population
WALTHAM, Mass., June 1, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a...
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology
21 mai 2009 02h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Reports First Quarter 2009 Financial Results
11 mai 2009 16h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., May 11, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces First Quarter 2009 Earnings Conference Call and Webcast
04 mai 2009 02h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor Activity in Animal Studies in Acute Myeloid Leukemia
22 avr. 2009 02h00 HE
|
Oxigene, Inc.
OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor
Activity in Animal Studies in Acute Myeloid Leukemia At the American
Association of Cancer Research Annual Meeting...
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent
06 avr. 2009 02h00 HE
|
Oxigene, Inc.
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular
Disrupting Agent
WALTHAM, Mass., April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN),
a clinical-stage...
OXiGENE Receives Qualified Opinion On Its Audited Financial Statements for 2008
30 mars 2009 16h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
OXiGENE Reports Fourth Quarter and Year-End 2008 Results
19 mars 2009 16h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., March 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC)
17 mars 2009 02h00 HE
|
Oxigene, Inc.
WALTHAM, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...